Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2022-2032

15 February 2022
Pharma

Visiongain has launched a new report 3D Cell Culture and 3D Bioprinting Market Report 2022-2032: Forecasts by Technology (Scaffold-Based, Scaffold-Free, Microfluidics-based, Magnetic Levitation, 3D Bioprinting, Others), by Application (Cancer and Stem Cell Research, Drug Discovery and Toxicology Testing, Tissue Engineering and Regenerative Medicine), by End-user (Pharmaceutical & Biotechnology Companies, Academic Institutes, Research Laboratories, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

Global 3D Cell Culture & 3D Bioprinting Market Outlook
According to Visiongain analysis, global 3D Cell Culture & 3D Bioprinting market was valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2032. The Global market is expected to grow at a CAGR of xx% during the forecast period 2022-2032.

How has COVID-19 had a significant negative impact on the 3D Cell Culture & 3D Bioprinting Market?
The COVID-19 pandemic has a significant negative impact on the 3D cell culture & 3D bioprinting market globally. The COVID-19 outbreak in 2020 led to international border controls, country-wide lockdowns, pharmaceutical manufacturing restrictions & limitations. This pandemic has hampered the production and distribution of 3D cell culture & 3D bioprinting technologies.

COVID-19 would undoubtedly have an effect on chronic and infectious diseases patients and their care for the near future. Creating support networks for physicians and patients will help to break down walls and provide patients with appropriate access to potentially life-saving services. Companies are concerned about the COVID-19 epidemic's impact on supply and demand. All of these factors are having a negative impact on the 3D cell culture & 3D bioprinting technologies sector, pushing the pharmaceutical industry and regulators to re-examine pharmaceutical supply chains.

How this Report Will Benefit you?
Visiongain’s 380+ page report provides 356 tables and 352 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global 3D cell culture & 3D bioprinting market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for 3D cell culture & 3D bioprinting technologies. Get the financial analysis of the overall market and different segments including technology, application, end user and capture higher market share. We believe that high opportunity remains in this fast-growing 3D cell culture & 3D bioprinting market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the current market drivers?

Use of 3D cell culture model in cancer research
Rise in cancer research, stem cell research, chronic diseases is expected to propel the demand for advanced 3D cell culture & 3D bioprinting technology. According to the WHO, the prevalence of chronic illness cases is expected to increase by 57%, with higher illness cases in low- & middle-income nations. Additionally, the outbreak of pandemics in the current & past such as COVID19, SARS, Ebola, MERS, and H1N1 have added to the upsurge in drug consumption and vaccination.

3D bioprinting for drug discovery and development in pharmaceutics
Usage convenience and cost-effectiveness of 3D bioprinting technology further driver the market adoption. Pharmaceutical companies like Corning Inc., Thermo Fisher Scientific Inc., Merck Group, and Lonza Group are constantly investing in development of 3D cell culture & 3D bioprinting technology to enhance the oral bioavailability of novel medicines using varied excipients. Also, the rising number of patients with chronic diseases along with growing healthcare awareness is projected to boost the demand for 3D cell culture & 3D bioprinting technology.

Where are the market opportunities?

3D Bioprinting for Animal-Free Meat
The day-to-day increased demand in the medical field for the bio alternatives that could be able to perform the living activities of bodily organs has raised the interest of the researchers to design novel biomaterials. So, market leaders are drifting from conventional techniques to the innovative and enhanced techniques, thereby developing the biocompatible and printable biomaterials.

Development of biocompatible and printable biomaterials
Organoids developed from pluripotent stem cells or adult stem cells are three-dimensional cell cultures possessing certain key characteristics of their organ counterparts, and they can mimic certain biological developmental processes of organs in vitro. Therefore, they have promising applications in drug screening, disease modeling, and regenerative repair of tissues and organs. The combination of bioprinting and organoids with a focus on structure and function can facilitate further development of real organs.

Competitive Landscape
The major players operating in the inflammatory bowel disease drugs market are Corning Inc., Thermi Fisher Scientific Inc., Merck Group, Lonza Group AG, Reprocell Inc., Organovo Inc., Cellink, Aspect Biosystems, EnvisionTEC, and Cyfuse Biomedical K.K.

These leading players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new drugs launch. For instance, October 2020, Merck collaborated with D1Med, a Shanghai-based biopharmaceutical start-up precision-medical company, to accelerate production of D1Med’s 3D cell culture technology applications used in the drug discovery process.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

Read

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever